TW201612167A - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane -2-carboxamides as dipeptidyl peptidase 1 inhibitors - Google Patents

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane -2-carboxamides as dipeptidyl peptidase 1 inhibitors

Info

Publication number
TW201612167A
TW201612167A TW104102345A TW104102345A TW201612167A TW 201612167 A TW201612167 A TW 201612167A TW 104102345 A TW104102345 A TW 104102345A TW 104102345 A TW104102345 A TW 104102345A TW 201612167 A TW201612167 A TW 201612167A
Authority
TW
Taiwan
Prior art keywords
oxazepane
phenylethyl
cyano
certain
dipeptidyl peptidase
Prior art date
Application number
TW104102345A
Other languages
English (en)
Other versions
TWI690517B (zh
Inventor
Hans Roland Lonn
Stephen Connolly
John Fritiof Ponten
Karlsson Staffan Po
Nicholas Palmer
Steven Swallow
Carl-Johan Aurell
Kevin Doyle
De Poel Amanda Van
Graham Jones
David Watson
Jaqueline Macritchie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201612167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW201612167A publication Critical patent/TW201612167A/zh
Application granted granted Critical
Publication of TWI690517B publication Critical patent/TWI690517B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW104102345A 2014-01-24 2015-01-23 作爲二肽基肽酶１抑制劑之特定（２ｓ）-ｎ-［（１ｓ）-１-氰基-２-苯基乙基］-１,４-氧氮雜環庚烷-２-甲醯胺 TWI690517B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
US61/931,090 2014-01-24

Publications (2)

Publication Number Publication Date
TW201612167A true TW201612167A (en) 2016-04-01
TWI690517B TWI690517B (zh) 2020-04-11

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104102345A TWI690517B (zh) 2014-01-24 2015-01-23 作爲二肽基肽酶１抑制劑之特定（２ｓ）-ｎ-［（１ｓ）-１-氰基-２-苯基乙基］-１,４-氧氮雜環庚烷-２-甲醯胺

Country Status (37)

Country Link
US (17) US9522894B2 (zh)
EP (3) EP3097086B1 (zh)
JP (5) JP6469711B2 (zh)
KR (1) KR102417684B1 (zh)
CN (2) CN105980367B (zh)
AP (1) AP2016009322A0 (zh)
AR (1) AR099177A1 (zh)
AU (4) AU2015208932C1 (zh)
BR (1) BR112016016224B1 (zh)
CA (1) CA2935625C (zh)
CL (1) CL2016001889A1 (zh)
CR (1) CR20160327A (zh)
CY (2) CY1120049T1 (zh)
DK (2) DK3097086T3 (zh)
DO (1) DOP2016000175A (zh)
EA (1) EA032794B1 (zh)
ES (2) ES2658516T3 (zh)
HK (2) HK1225730B (zh)
HR (2) HRP20180116T1 (zh)
HU (2) HUE038274T2 (zh)
IL (3) IL246614B (zh)
LT (2) LT3097086T (zh)
MX (1) MX368840B (zh)
MY (1) MY194850A (zh)
NO (1) NO2699580T3 (zh)
NZ (2) NZ722063A (zh)
PE (1) PE20161218A1 (zh)
PH (1) PH12016501439A1 (zh)
PL (2) PL3323814T3 (zh)
PT (2) PT3323814T (zh)
RS (2) RS56919B1 (zh)
SG (2) SG10201701056QA (zh)
SI (2) SI3323814T1 (zh)
TW (1) TWI690517B (zh)
UY (1) UY35963A (zh)
WO (1) WO2015110826A1 (zh)
ZA (2) ZA201605856B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (zh) 2014-01-24 2018-02-24
US20180028541A1 (en) * 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
US20200390781A1 (en) * 2018-02-07 2020-12-17 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
EP3758708A1 (en) * 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
JP2021530513A (ja) * 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
KR20210032431A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
AU2020370210A1 (en) * 2019-10-23 2022-04-21 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (COPD)
JP2023535332A (ja) * 2020-07-20 2023-08-17 インスメッド インコーポレイテッド 好中球セリンプロテアーゼを抽出するおよびジペプチジルペプチダーゼ１媒介性病態を治療するための方法
IL300855A (en) 2020-08-26 2023-04-01 Haisco Pharmaceuticals Pte Ltd A nitrile derivative acting as an inhibitor of DIPEPTIDYL PEPTIDASE 1 and its use
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
JP2023551488A (ja) 2020-12-04 2023-12-08 瑞石生物医薬有限公司 カテプシンｃの小分子阻害剤及びその医薬的使用
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CA3207466A1 (en) * 2021-02-05 2022-08-11 Lingyun Wu Fused ring derivatives containing 1,4-oxazepane
CA3236069A1 (en) * 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
WO2023134656A1 (zh) * 2022-01-11 2023-07-20 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
WO2023159120A1 (en) * 2022-02-16 2023-08-24 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
WO2023160541A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种含氮杂环化合物的制备方法
WO2023160579A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
WO2023236879A1 (zh) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 苯并[c]色满化合物的多晶型及其制备方法和用途
TW202404961A (zh) * 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的可藥用鹽、其多晶型及用途
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
ATE378411T1 (de) 2000-09-08 2007-11-15 Prozymex As Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1453801B1 (en) 2001-12-04 2007-03-21 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
EP1633702B1 (en) 2003-05-30 2008-07-02 Prozymex A/S Protease inhibitors
US20070099958A1 (en) * 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
MXPA06011463A (es) 2004-04-07 2007-04-25 Rinat Neuroscience Corp Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
MXPA06015131A (es) 2004-06-29 2007-03-26 Nycomed Danmark Aps Manufactura de composiciones farmaceuticas con liberacion precipitada de farmacos insolubles en agua y composiciones farmaceuticas obtenidas por medio del proceso de la invencion.
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
DK2301531T3 (en) 2005-02-18 2018-07-30 Abraxis Bioscience Llc COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
EP2125816A2 (en) 2007-03-07 2009-12-02 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
AU2008305591A1 (en) 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
MX2010006110A (es) 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
RU2586212C2 (ru) 2008-12-08 2016-06-10 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
CN105816456A (zh) 2009-04-01 2016-08-03 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
EP2427445A1 (en) * 2009-05-07 2012-03-14 AstraZeneca AB Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
CN103491777B (zh) 2011-02-11 2015-05-06 葛兰素史密斯克莱知识产权发展有限公司 组织蛋白酶c抑制剂
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2013124026A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
WO2013157562A1 (ja) 2012-04-17 2013-10-24 アステラス製薬株式会社 含窒素二環式芳香族へテロ環化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
JP6441831B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
WO2014140081A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014140078A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
WO2015032945A1 (en) 2013-09-09 2015-03-12 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
NO2699580T3 (zh) 2014-01-24 2018-02-24
US9895385B2 (en) 2014-05-15 2018-02-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
EP3149192B1 (en) 2014-05-30 2019-01-02 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
PE20170438A1 (es) 2014-09-12 2017-04-28 Boehringer Ingelheim Int Inhibidores espirociclicos de catepsina c
EA032104B1 (ru) 2014-11-14 2019-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
AU2016227618B2 (en) 2015-03-05 2020-06-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
US20180028541A1 (en) 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
US20200390781A1 (en) 2018-02-07 2020-12-17 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
EP3758708A1 (en) 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
JP2021530513A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
EP4329767A1 (en) 2021-04-29 2024-03-06 Insmed Incorporated Certain-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis

Also Published As

Publication number Publication date
CY1120049T1 (el) 2018-12-12
US20230062646A1 (en) 2023-03-02
US11680049B2 (en) 2023-06-20
JP2019070029A (ja) 2019-05-09
JP2023156479A (ja) 2023-10-24
AU2015208932A1 (en) 2016-07-28
SI3097086T1 (en) 2018-04-30
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
CA2935625C (en) 2022-10-18
BR112016016224A2 (zh) 2017-08-08
HUE052421T2 (hu) 2021-04-28
SI3323814T1 (sl) 2020-10-30
US20240132455A1 (en) 2024-04-25
PH12016501439B1 (en) 2017-02-06
TWI690517B (zh) 2020-04-11
CN105980367B (zh) 2019-08-23
AU2017200338A1 (en) 2017-02-02
US20230085620A1 (en) 2023-03-23
MX2016009349A (es) 2016-10-13
AR099177A1 (es) 2016-07-06
EA032794B1 (ru) 2019-07-31
EP3097086A1 (en) 2016-11-30
US20230069044A1 (en) 2023-03-02
AU2015208932A8 (en) 2017-03-09
CN105980367A (zh) 2016-09-28
US9522894B2 (en) 2016-12-20
IL252836A0 (en) 2017-08-31
US20230025351A1 (en) 2023-01-26
CN110483492A (zh) 2019-11-22
MY194850A (en) 2022-12-19
DOP2016000175A (es) 2016-08-15
US20150210655A1 (en) 2015-07-30
DK3097086T3 (en) 2018-02-05
EP3097086B1 (en) 2017-12-13
WO2015110826A1 (en) 2015-07-30
NZ722063A (en) 2017-09-29
AU2019202675A1 (en) 2019-05-16
SG10201701056QA (en) 2017-03-30
EP3323814A1 (en) 2018-05-23
ZA201605856B (en) 2020-02-26
KR20160111470A (ko) 2016-09-26
EP3323814B1 (en) 2020-05-13
KR102417684B1 (ko) 2022-07-05
US11667615B2 (en) 2023-06-06
CA2935625A1 (en) 2015-07-30
US20200017455A1 (en) 2020-01-16
US11655222B2 (en) 2023-05-23
MX368840B (es) 2019-10-18
AU2015208932C1 (en) 2017-05-25
US11655223B2 (en) 2023-05-23
PT3323814T (pt) 2020-08-05
RS56919B1 (sr) 2018-05-31
US20230116721A1 (en) 2023-04-13
AU2017200338B2 (en) 2018-03-01
US20180251436A1 (en) 2018-09-06
HK1255870A1 (zh) 2019-08-30
AU2019202675B2 (en) 2020-05-28
IL265611A (en) 2019-05-30
ES2808060T3 (es) 2021-02-25
AU2015208932B8 (en) 2017-03-09
PL3323814T3 (pl) 2020-10-19
JP2021046423A (ja) 2021-03-25
US20230115170A1 (en) 2023-04-13
US20230028726A1 (en) 2023-01-26
US20210238152A1 (en) 2021-08-05
JP2022096662A (ja) 2022-06-29
EA201691375A1 (ru) 2017-01-30
JP2017503832A (ja) 2017-02-02
CY1123391T1 (el) 2021-12-31
ES2658516T3 (es) 2018-03-12
HRP20201147T1 (hr) 2020-12-11
NZ734768A (en) 2022-09-30
US20200247765A1 (en) 2020-08-06
DK3323814T3 (da) 2020-08-03
UY35963A (es) 2015-07-31
JP7336563B2 (ja) 2023-08-31
CL2016001889A1 (es) 2016-12-09
AU2015208932B2 (en) 2017-02-16
LT3323814T (lt) 2020-10-26
US20230250071A1 (en) 2023-08-10
PH12016501439A1 (en) 2017-02-06
US11655221B2 (en) 2023-05-23
NO2699580T3 (zh) 2018-02-24
US10669245B2 (en) 2020-06-02
SG11201606052TA (en) 2016-08-30
RS60639B1 (sr) 2020-09-30
US11673871B2 (en) 2023-06-13
LT3097086T (lt) 2018-02-26
US9815805B2 (en) 2017-11-14
JP7157791B2 (ja) 2022-10-20
US20230033573A1 (en) 2023-02-02
US10287258B2 (en) 2019-05-14
US11814359B2 (en) 2023-11-14
PT3097086T (pt) 2018-02-21
JP6804570B2 (ja) 2020-12-23
CR20160327A (es) 2016-10-20
ZA201800431B (en) 2019-09-25
JP6469711B2 (ja) 2019-02-13
PE20161218A1 (es) 2016-11-27
PL3097086T3 (pl) 2018-04-30
EP3744714A1 (en) 2020-12-02
US11117874B2 (en) 2021-09-14
US11773069B2 (en) 2023-10-03
CN110483492B (zh) 2023-07-21
AU2018202956A1 (en) 2018-05-17
HRP20180116T1 (hr) 2018-03-23
AP2016009322A0 (en) 2016-07-31
US20170057938A1 (en) 2017-03-02
US11655224B2 (en) 2023-05-23
AU2018202956B2 (en) 2019-05-09
US20230278969A1 (en) 2023-09-07
US11673872B2 (en) 2023-06-13
HK1225730B (zh) 2017-09-15
BR112016016224B1 (pt) 2023-02-23

Similar Documents

Publication Publication Date Title
PH12016501439A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12018501812A1 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12015500387A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2018010894A (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2016014696A (es) Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
NZ724063A (en) Pyrazine derivatives having pharmaceutical activity